Canaccord Genuity Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $39
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsInitiationPrice Target
Canaccord Genuity analyst John Newman initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $39.
Canaccord Genuity analyst John Newman initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $39.